Canine CCL5/RANTES Antibody

Catalog #: MAB60451 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB60451
MAB60451-SP

1 Image

All CCL5/RANTES Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Canine CCL5/RANTES Antibody Summary

Species Reactivity

Canine

Specificity

Detects canine CCL5/RANTES in direct ELISAs. In Western blots, no cross-reactivity with recombinant CCL5/RANTES from cat, cotton rat, mouse, or human is observed. No cross-reactivity with recombinant mouse CCL7/MARC, rmCCL17/TARC, recombinant human (rh) CCL18/PARC, or rhCCL17/TARC is observed.

Source

Monoclonal Mouse IgG₁ Clone # 676106

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

E. coli-derived recombinant canine CCL5/RANTES
Ser24-Ser91
Accession # Q8HYS0

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Applications

Recommended Concentration

Sample

Immunocytochemistry

8-25 µg/mL

See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Immunocytochemistry

View Larger

CCL5/RANTES in Canine PBMCs. CCL5/RANTES was detected in immersion fixed canine peripheral blood mononuclear cells (PBMCs) treated with calcium ionomycin and PMA using Canine CCL5/RANTES Monoclonal Antibody (Catalog # MAB60451) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Sterile PBS to a final concentration of 0.5 mg/mL.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL5/RANTES

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1‑3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature canine CCL5 shares 74%‑84% amino acid seqeuence identity with cotton rat, feline, human, mouse, and rat CCL5. CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (5, 6). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (7). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (8). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (9). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (10‑12). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (13‑15). CCL5 is up‑regulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (16).

References

Schall, T.J. et al. (1990) Nature 347:669.
Bacon, K.B. et al. (1995) Science 269:1727.
Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
Levy, J.A. (2009) J. Immunol. 182:3945.
Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401.
Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885.
von Hundelshausen, P. et al. (2005) Blood 105:924.
von Hundelshausen, P. et al. (2001) Circulation 103:1772.
Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
Baltus, T. et al. (2003) Blood 102:1985.
Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.

Entrez Gene IDs

6352 (Human); 20304 (Mouse); 403522 (Canine); 493689 (Feline)

Alternate Names

CCL5; chemokine (C-C motif) ligand 5; D17S136Enormally T-expressed, and presumably secreted; EoCP; Eosinophil chemotactic cytokine; RANTES; SISd; SIS-delta; small inducible cytokine A5 (RANTES); small inducible cytokine subfamily A (Cys-Cys), member 5; Small-inducible cytokine A5; T cell-specific protein P228; T-cell specific protein p288; TCP228T-cell-specific protein RANTES